Suzhou Huajianruida Pharmaceutical Technology

Suzhou Huajianruida Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on the discovery and development of novel small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platform to target complex biological pathways in immunology and metabolism. Its lead program, HJRD-002, is a potent and selective TYK2 inhibitor designed to treat autoimmune diseases such as psoriasis and inflammatory bowel disease. Another key asset, HJRD-001, targets GPR119 for the management of type 2 diabetes and metabolic disorders. By integrating advanced computational chemistry with deep biological insights, Huajianruida aims to deliver high-quality, differentiated therapeutics to patients worldwide. The company is supported by prominent regional investors and is situated within the Suzhou BioBAY ecosystem.